Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor-Reference-Cited by-同舟云学术

Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor

Published:2001-12-01 Issue:11 Volume:167 Page:6669-6677
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J Immunol

Author:

Kjaergaard Jørgen,Peng Liaomin,Cohen Peter A.,Drazba Judith A.,Weinberg Andrew D.,Shu Suyu

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference53 articles.

1. Gene therapy: current status and future prospects

2. Considerations for the Use of Cytokine-Secreting Tumor Cell Preparations for Cancer Treatment

3. Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene.

4. Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity;ACS Biomaterials Science & Engineering;2022-06-02

2. Role of OX40 and its ligand as costimulatory modulators in cancer immunotherapy;AIMS Molecular Science;2021

3. Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms;Cellular & Molecular Immunology;2020-05-20

4. Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression;Science Translational Medicine;2019-06-05

5. Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers;Frontiers in Oncology;2018-11-28